Decision on Plan B Called Very Unusual
By Marc Kaufman
Washington Post Staff Writer
Thursday, October 13, 2005; A09

A long-awaited report on the 2004 Food and Drug Administration decision to reject an application to allow easier access to the "morning after pill" concludes that the decision was highly unusual, was made with atypical involvement from top agency officials, and may well have been made months before it was formally announced.

...As described by some familiar with the draft, the GAO found that top FDA officials participated in assessing the application to allow the emergency contraceptive Plan B to be sold without a prescription, and that such unusual high-level involvement was justified by the perceived sensitivity of the issue.

...While an FDA advisory panel overwhelmingly supported the proposal in late 2003 on scientific grounds and the agency's medical reviewers were similarly convinced it should be approved, the agency's top leaders have said it could not be approved because of outstanding questions about whether it should be available to young girls, and if not, how to keep it from them.

When Steven Galson, then-acting director of the Center for Drug Evaluation and Research, announced the rejection, he said the decision was his own, had been recently made and was based on scientific concerns. The GAO report, however, indicates the decision was solidified months earlier and that other top officials were involved in the decision.